Avandia to Carry Black Box Warning
The Food and Drug Administration has ordered tougher warnings for diabetes drug Avandia (rosiglitazone), as well as a similar drug, Actos. The new mandate was announced by FDA Commissioner Andrew von Eschenbach at a congressional hearing yesterday, where the FDA was being scrutinized and questioned about why it didn't act sooner even though outside experts drew attention to cardiac risks years ago. "The FDA dropped the ball," said Rep. Henry Waxman, the California Democrat who heads the oversight committee that held yesterday's hearing.
